{"id":"cg5503","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, CG5503 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"CG5503 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:26.090Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06240390","phase":"NA","title":"Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain","status":"WITHDRAWN","sponsor":"Universidad Europea de Canarias","startDate":"2024-05-01","conditions":"Pain Cancer","enrollment":""},{"nctId":"NCT07338084","phase":"","title":"OpioidRedoxStudyII","status":"NOT_YET_RECRUITING","sponsor":"EPC Education s.r.o.","startDate":"2026-06-30","conditions":"Oxidative Stress, Opioid Use","enrollment":120},{"nctId":"NCT07320781","phase":"NA","title":"Role of Preoperative Tapentadol in Reduction of Perioperative Analgesic Requirement After Breast Conservative Surgery in Cancer Patients.","status":"COMPLETED","sponsor":"Shaukat Khanum Memorial Cancer Hospital & Research Centre","startDate":"2024-11-15","conditions":"Breast Cancer","enrollment":70},{"nctId":"NCT07123805","phase":"NA","title":"ACU_Knee: Role of Acupuncture in Knee Prosthetic Surgery","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2024-04-10","conditions":"Acupuncture Analgesia, Acupuncture, Acupuncture Therapy","enrollment":80},{"nctId":"NCT03020875","phase":"PHASE4","title":"IV vs Oral Acetaminophen in Spine Fusion Perioperative Care","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital for Special Surgery, New York","startDate":"2017-01","conditions":"Multimodal Analgesic Approach","enrollment":166},{"nctId":"NCT01458015","phase":"PHASE4","title":"Tapentadol Versus Oxycodone - a Mechanism-based Treatment Approach in Neuropathic Pain","status":"TERMINATED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2011-10","conditions":"Peripheral Neuropathy","enrollment":3},{"nctId":"NCT06269770","phase":"PHASE4","title":"Tapentadol vs Tramadol in Total Knee Arthroplasty","status":"RECRUITING","sponsor":"University of Thessaly","startDate":"2023-05-01","conditions":"Total Knee Replacement, Post-operative Pain, Chronic Pain","enrollment":96},{"nctId":"NCT06227208","phase":"","title":"Postoperative Opioid and Respiratory Depression in Opioid Naive and Chronic Opioid Patients","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2023-10-01","conditions":"Medical Complication","enrollment":691},{"nctId":"NCT05999890","phase":"PHASE4","title":"Comparison of Postoperative Analgesia Between Intravenous Paracetamol and Intranasal Tapentadol","status":"COMPLETED","sponsor":"Kempegowda Institute of Medical Sciences, Bangalore","startDate":"2021-07-05","conditions":"Lower Limb Fracture","enrollment":74},{"nctId":"NCT02277080","phase":"","title":"The Immune and Endocrine Systems in Chronic Non-cancer Patients Treated With Opioids","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2014-09","conditions":"Pain, Opioids, Immune System","enrollment":82},{"nctId":"NCT04718116","phase":"NA","title":"Tapentadol Versus Tramadol Analgesia Post Cardiac Surgery","status":"UNKNOWN","sponsor":"Aretaieion University Hospital","startDate":"2022-11-01","conditions":"Postoperative Pain, Surgery, Pain, Postoperative","enrollment":90},{"nctId":"NCT01615510","phase":"PHASE1","title":"Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models","status":"TERMINATED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2012-10","conditions":"Pain, Hyperalgesia, Allodynia","enrollment":24},{"nctId":"NCT03814993","phase":"","title":"taPentadol cLinical prAcTice IN belgiUM","status":"COMPLETED","sponsor":"Dafne Balemans","startDate":"2019-07-29","conditions":"Severe Pain Syndromes","enrollment":55},{"nctId":"NCT02604446","phase":"PHASE3","title":"Depot-opioids for Pre- and Postoperative Pain Relief After Primary Knee Arthroplasty.Tapentadol vs Oxycodone vs Placebo","status":"COMPLETED","sponsor":"St. Olavs Hospital","startDate":"2015-09","conditions":"Joint Diseases","enrollment":134},{"nctId":"NCT01725087","phase":"PHASE2","title":"Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2012-11","conditions":"Low Back Pain","enrollment":1089},{"nctId":"NCT03604354","phase":"PHASE4","title":"Safety and Efficacy of Pre-emptive Tapentadol vs Pregabalin in Post Operative Pain Following Surgery","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2018-08-01","conditions":"Osteoarthritis, Knee","enrollment":95},{"nctId":"NCT02081391","phase":"PHASE3","title":"A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2015-02-19","conditions":"Acute Pain","enrollment":216},{"nctId":"NCT01264887","phase":"PHASE3","title":"Tapentadol in Chronic Malignant Tumour Related Pain","status":"TERMINATED","sponsor":"Grünenthal GmbH","startDate":"2011-03","conditions":"Cancer, Chronic Pain, Pain","enrollment":31},{"nctId":"NCT00472303","phase":"PHASE3","title":"A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2007-07","conditions":"Tumor, Pain","enrollment":622},{"nctId":"NCT01729728","phase":"PHASE2","title":"Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2012-11","conditions":"Postoperative Pain, Acute Pain","enrollment":86},{"nctId":"NCT00505414","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine","status":"TERMINATED","sponsor":"Grünenthal GmbH","startDate":"2007-06","conditions":"Pain, Neoplasm, Cancer","enrollment":136},{"nctId":"NCT01352741","phase":"PHASE4","title":"Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2011-03","conditions":"Low Back Pain, Neuropathic Pain","enrollment":622},{"nctId":"NCT01435577","phase":"PHASE2","title":"Intravenous Tapentadol in Post-Bunionectomy Pain","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2011-09","conditions":"Bunion, Pain","enrollment":177},{"nctId":"NCT00478023","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2007-05","conditions":"Hysterectomy, Postoperative","enrollment":854},{"nctId":"NCT00983073","phase":"PHASE3","title":"Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2009-09","conditions":"Chronic Pain, Osteoarthritis","enrollment":224},{"nctId":"NCT00982280","phase":"PHASE3","title":"Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.","status":"TERMINATED","sponsor":"Grünenthal GmbH","startDate":"2009-09","conditions":"Chronic Pain, Osteoarthritis","enrollment":82},{"nctId":"NCT00486811","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2007-06","conditions":"Pain, Knee Osteoarthritis","enrollment":990},{"nctId":"NCT02151682","phase":"PHASE2, PHASE3","title":"A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2015-04-29","conditions":"Pain","enrollment":73},{"nctId":"NCT03979989","phase":"PHASE1","title":"Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2005-09-28","conditions":"Pharmacokinetic","enrollment":32},{"nctId":"NCT03956134","phase":"PHASE1","title":"Pharmacokinetic Characterization of Two Novel CG5503 Tablet Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2005-04","conditions":"Pharmacokinetics","enrollment":10},{"nctId":"NCT03951402","phase":"PHASE1","title":"Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2003-03","conditions":"Prolonged QTc Interval, Pharmacokinetic","enrollment":48},{"nctId":"NCT03951987","phase":"PHASE1","title":"Investigation How CG5503 is Taken up and Excreted From the Body After 2 Minutes Intravenous Infusion With and Without Oral Co-administration of Charcoal","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2004-02","conditions":"Pharmacokinetic","enrollment":14},{"nctId":"NCT03314792","phase":"PHASE4","title":"Effects of Tapentadol Versus Oxycodone After Hysterectomy.","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2017-12-04","conditions":"Pain, Postoperative, Pain Uterus, Pain, Acute","enrollment":86},{"nctId":"NCT00983385","phase":"PHASE3","title":"Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2009-09-30","conditions":"Chronic Pain, Low Back Pain","enrollment":208},{"nctId":"NCT00986258","phase":"PHASE3","title":"Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability","status":"TERMINATED","sponsor":"Grünenthal GmbH","startDate":"2009-10-30","conditions":"Pain, Chronic Pain, Low Back Pain","enrollment":136},{"nctId":"NCT03351517","phase":"NA","title":"Preemptive Tapentadol on Post-operative Analgesia Following Total Knee Arthroplasty","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2017-11-01","conditions":"Analgesia","enrollment":90},{"nctId":"NCT02221674","phase":"PHASE2","title":"Use of Tapentadol Oral Solution for Pain After Surgery in Children From Newborn to Less Than 2 Years Old","status":"TERMINATED","sponsor":"Grünenthal GmbH","startDate":"2014-11-05","conditions":"Moderate to Severe Acute Postoperative Pain","enrollment":40},{"nctId":"NCT01631513","phase":"PHASE4","title":"An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)","status":"WITHDRAWN","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2012-08","conditions":"Pain, Chronic Back Pain, Chronic Low Back Pain","enrollment":""},{"nctId":"NCT03121547","phase":"PHASE1, PHASE2","title":"Opioid Induced Gait Variability","status":"COMPLETED","sponsor":"Frederiksberg University Hospital","startDate":"2015-05-19","conditions":"Opioid Induced Motor Disturbances","enrollment":24},{"nctId":"NCT01165281","phase":"PHASE3","title":"A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-08","conditions":"Pain","enrollment":343},{"nctId":"NCT02920762","phase":"","title":"Evaluation of Changes in Prescribing Behavior of ER/LA Opioid Prescribers","status":"UNKNOWN","sponsor":"ER/LA Opioid REMS Program Companies (RPC)","startDate":"","conditions":"Opioid Related Disorders, Opiate Addiction, Narcotic Abuse","enrollment":5575834},{"nctId":"NCT01946555","phase":"","title":"Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2013-09","conditions":"Tumor, Cancer Pain, Breakthrough Cancer Pain","enrollment":150},{"nctId":"NCT01838616","phase":"PHASE4","title":"Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2013-04","conditions":"Back Pain, Low Back Pain, Neuropathic Pain","enrollment":367},{"nctId":"NCT01719588","phase":"","title":"A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain","status":"WITHDRAWN","sponsor":"Janssen Pharmaceutica","startDate":"2014-10","conditions":"Moderate to Severe Chronic Non-cancer Pain","enrollment":""},{"nctId":"NCT01719601","phase":"","title":"A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain","status":"WITHDRAWN","sponsor":"Janssen Pharmaceutica","startDate":"2014-10","conditions":"Moderate to Severe Acute Non-Cancer Pain","enrollment":""},{"nctId":"NCT00594516","phase":"PHASE3","title":"Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-12","conditions":"Low Back Pain","enrollment":117},{"nctId":"NCT01813890","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2013-01","conditions":"Hallux Valgus","enrollment":60},{"nctId":"NCT01134536","phase":"PHASE2","title":"Pharmacokinetics and Safety Study of Tapentadol for Postsurgical Pain in Children and Adolescents","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-10","conditions":"Pain, Postoperative, Postoperative Pain","enrollment":45},{"nctId":"NCT00771758","phase":"PHASE3","title":"Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis","status":"COMPLETED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2008-09","conditions":"Back Pain","enrollment":108},{"nctId":"NCT00487435","phase":"PHASE3","title":"An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-06","conditions":"Pain, Osteoarthritis, Low Back Pain","enrollment":1166},{"nctId":"NCT00613938","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-02","conditions":"Arthralgia, Bunion, Hallux Valgus","enrollment":901},{"nctId":"NCT00361504","phase":"PHASE3","title":"A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-11","conditions":"Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain","enrollment":1123},{"nctId":"NCT01516008","phase":"PHASE3","title":"A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-01","conditions":"Hallux Valgus","enrollment":353},{"nctId":"NCT00364533","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-10","conditions":"Arthroplasty","enrollment":367},{"nctId":"NCT01063868","phase":"PHASE3","title":"A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-01","conditions":"Diabetic Neuropathy, Painful, Diabetic Polyneuropathy","enrollment":47},{"nctId":"NCT01309425","phase":"PHASE1","title":"A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-02","conditions":"Healthy Volunteer","enrollment":52},{"nctId":"NCT01124617","phase":"PHASE2","title":"A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2010-06","conditions":"Pain, Diabetic Neuropathies, Neuralgia","enrollment":91},{"nctId":"NCT02019485","phase":"PHASE1","title":"A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-07","conditions":"Healthy","enrollment":64},{"nctId":"NCT01981278","phase":"PHASE1","title":"A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-07","conditions":"Healthy","enrollment":63},{"nctId":"NCT01900587","phase":"PHASE1","title":"A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-07","conditions":"Healthy","enrollment":64},{"nctId":"NCT01041859","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2009-12","conditions":"Diabetic Peripheral Neuropathy","enrollment":460},{"nctId":"NCT00805142","phase":"PHASE2","title":"Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-11","conditions":"Pain, Cancer","enrollment":78},{"nctId":"NCT00455520","phase":"PHASE3","title":"A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-04","conditions":"Diabetic Neuropathy","enrollment":395},{"nctId":"NCT01877226","phase":"PHASE1","title":"Phase 1 Pharmacokinetic Study of Tapentadol Prolonged-Release 250 Milligram (mg) Formulation in Healthy Participants","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-09","conditions":"Healthy","enrollment":18},{"nctId":"NCT01124604","phase":"PHASE2","title":"An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2010-04","conditions":"Pain, Low Back Pain, Back Pain","enrollment":91},{"nctId":"NCT01309386","phase":"PHASE3","title":"A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2010-08","conditions":"Neoplasms","enrollment":100},{"nctId":"NCT00986180","phase":"PHASE3","title":"NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain","status":"COMPLETED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2009-09","conditions":"Pain, Back Pain, Low Back Pain","enrollment":667},{"nctId":"NCT01500317","phase":"PHASE4","title":"Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2011-05","conditions":"Effects of 2 Mu-opiates on Gastrointestinal Transit","enrollment":38},{"nctId":"NCT00814580","phase":"PHASE3","title":"Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery","status":"COMPLETED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2008-12","conditions":"Postoperative Pain","enrollment":382},{"nctId":"NCT01545778","phase":"","title":"Risk of Shopping Behavior of Tapentadol Immediate-Release (IR) Compared to Oxycodone Immediate-Release (IR)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-02","conditions":"Substance Abuse Detection","enrollment":646620},{"nctId":"NCT00449176","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-02","conditions":"Low Back Pain","enrollment":981},{"nctId":"NCT00421928","phase":"PHASE3","title":"Tapentadol (CG5503)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-01","conditions":"Osteoarthritis, Knee, Pain","enrollment":1030},{"nctId":"NCT01273506","phase":"PHASE1","title":"A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 25-mg Tablets Relative to One 50-mg Tablet","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-12","conditions":"Healthy Volunteer","enrollment":30},{"nctId":"NCT01273532","phase":"PHASE1","title":"A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-12","conditions":"Healthy Volunteer","enrollment":30},{"nctId":"NCT00784277","phase":"PHASE3","title":"A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-10","conditions":"Joint Diseases, Arthritis, Osteoarthritis","enrollment":597},{"nctId":"NCT00609466","phase":"PHASE3","title":"A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2007-09","conditions":"Bunionectomy, Pain, Postoperative Pain","enrollment":291},{"nctId":"NCT00361582","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-10","conditions":"Osteoarthritis, Pain Assessment, Arthralgia","enrollment":669},{"nctId":"NCT00364546","phase":"PHASE3","title":"A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-07","conditions":"Osteoarthritis, Pain Intensity Assessment, Arthralgia","enrollment":877},{"nctId":"NCT00364247","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo Followed by a Voluntary Open Label Extension for Safety.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Arthralgia, Bunion, Hallux Valgus","enrollment":602},{"nctId":"NCT00745069","phase":"PHASE2","title":"Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-07","conditions":"Osteoarthitis, Chronic Pain, Knee Pain","enrollment":670},{"nctId":"NCT00806247","phase":"PHASE2","title":"A Randomized, Double-Blind, Parallel-Arm, Placebo and Active Controlled Dose-Ranging Study of the Efficacy and Safety of Multiple Doses of Tapentadol IR for Postoperative Pain Following Bunionectomy Surgery","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2005-01","conditions":"Pain, Postoperative Pain","enrollment":480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CG5503","genericName":"CG5503","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CG5503 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}